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ABSTRACT
Purpose: Brostallicin (PNU-166196) is a cytotoxic agent
that binds to the minor groove of DNA with significant
antitumor activity in preclinical studies. This trial was de-
signed to determine the maximum tolerated dose, the toxic-
ity profile, and the pharmacokinetics of Brostallicin in can-
cer patients.
Experimental Design: Patients were treated with esca-
lating doses of Brostallicin ranging from 0.85 to 15 mg/m2
administered as a 10-min i.v. infusion every 3 weeks. Blood
samples for pharmacokinetic analysis were collected during
the first and second course, and analyzed by liquid-chroma-
tography with tandem-mass spectrometric detection.
Results: Twenty-seven evaluable patients received a to-
tal of 73 courses. Grade 4 neutropenia was the only dose-
limiting toxicity at 12.5 mg/m2, whereas grade 4 thrombo-
cytopenia (1 patient) and grade 4 neutropenia (2 patients)
were the dose-limiting toxicities at 15 mg/m2. Other side
effects, including thrombocytopenia and nausea, were gen-
erally mild. The maximum tolerated dose was defined at 10
mg/m2. The clearance and terminal half-life of Brostallicin
were dose-independent, with mean (SD) values of 9.33 
2.38 liters/h/m2 and 4.69  1.88 h, respectively. There was
no significant accumulation of Brostallicin with repeated
administration. Significant relationships were observed
between systemic exposure to Brostallicin and neutrophil
counts at nadir. One partial response was observed in a
patient with a gastrointestinal stromal tumor.
Conclusion: Brostallicin was found to be well tolerated,
with neutropenia being the principal toxicity. The recom-
mended dose for additional evaluation in this schedule is 10
mg/m2.
INTRODUCTION
Brostallicin (PNU-166196) is a new synthetic -bromo-
acrylic derivative of distamycin A-like structures, characterized
by a four-unit pyrrolcarbamoyl frame ending with a guanidine
moiety (Fig. 1). It belongs to the class of DNA MGBs,4 which
comprises synthetic and semisynthetic compounds of very dif-
ferent molecular structure, acting through different mechanisms.
Although MGB alkylating compounds (e.g., tallimustine,
carselezin, and adozelesin) have shown excellent antitumor
activity in preclinical studies, they have failed to demonstrate
relevant antitumor activity in clinical trials because of severe
myelotoxicity preventing the administration of potentially ther-
apeutic doses (1–7).
Brostallicin has been selected for clinical development
because of its reduced myelotoxicity in comparison with other
MGBs in preclinical models translating into an 80-fold increase
of therapeutic index in comparison with tallimustine (8).
In preclinical experiments, Brostallicin exerts antitumor
activity against several murine and human tumor xenografts (8)
Brostallicin is also highly proapoptotic (more than campto-
thecin) and, unlike alkylating agents and other MGBs, is fully
active against DNA mismatch repair-deficient tumor cells (9–
12). Brostallicin is more effective against cell sublines selected
for resistance to alkylating agents and expressing high levels of
GSH. Interestingly, it was found that Brostallicin reacts in vitro
with GSH, but instead of causing inactivation of the drug, as one
might expect, this reaction increases its cytotoxicity and the
antitumor effect. The reaction between Brostallicin and GSH is
catalyzed by GST with the  and  isoenzymes being more
effective than the  isoenzyme. Isogenic cell systems differing
only for the expression of GST- isoenzyme, allowed the ver-
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ification that the greater sensitivity to Brostallicin occurs not
only in in vitro cultured cells but also in tumors transplanted in
nude mice (13, 14). This might be important clinically, as GSH
and GST overexpression in comparison with normal tissues
occurs de novo or as a consequence of cytotoxic treatment in a
number of cancers, and GST- is the most prevalent GST
isoenzyme in tumors (15, 16).
Preclinical toxicology studies in mice and monkeys iden-
tified the hematopoietic system as the principal target of Bros-
tallicin toxicity, mainly affecting the white cell lineage and
much less frequently PLTs. The LD10 of a single administration
of Brostallicin in mice were 3.54 and 2.86 mg/kg in males and
females, respectively (10.6 and 8.6 mg/m2).
We performed a dose-finding and pharmacological study to
evaluate the toxicity of 3-weekly i.v. administration of Brostal-
licin, to determine the MTD, to describe the pharmacokinetics
of Brostallicin, to document any antitumor effects, and to es-
tablish a dose suitable for additional Phase II evaluation of
activity of the compound.
PATIENTS AND METHODS
Eligibility Criteria. Patients with a cytologically or his-
tologically confirmed diagnosis of a solid tumor refractory to
standard treatment or for whom no standard treatment was
available were eligible for this study. Patients with primary
central nervous system neoplasm, brain or leptomeningeal me-
tastases, or known bone marrow involvement were excluded.
Additional eligibility criteria included the following: age 18
years; Eastern Cooperative Oncology Group performance status
2; life expectancy of 12 weeks; no anticancer therapy in
the previous 4 weeks; adequate bone marrow function (ANC
1.5  109/liter and PLT 100  109/liter); adequate liver
function (total bilirubin 20 mol/liter, AST and ALT within
the normal limits or up to 2.5 upper normal limit in case of liver
metastasis); adequate renal function (serum creatinine 133
mol/liter); no more than two prior heavily myelosuppressive
chemotherapeutic regimens; no prior high dose chemotherapy
requiring bone marrow rescue; and no radiotherapy involving
25% of bone marrow. Concomitant use of growth factors was
not allowed. The institutional medical ethics committee ap-
proved the protocol. All of the patients gave written informed
consent at study entry.
Treatment Assessment. Before therapy, a complete
medical history was taken, and a physical examination was
performed. A complete blood count, including WBC differ-
ential, and serum chemistry, including sodium, potassium,
calcium, phosphorus, urea, creatinine, total protein, albumin,
glucose, alkaline phosphatase, bilirubin, AST, ALT, and -
glutamyl transferase were performed, as were urine analysis,
electrocardiogram, and chest X-ray. Weekly evaluations in-
cluded history, physical examination, toxicity assessment
according to the National Cancer Institute Common Toxicity
Criteria (version date January 1998), serum chemistries, urine
analysis, and electrocardiogram. Complete blood counts and
liver function tests were taken twice weekly in the first three
cycles and weekly thereafter. Tumor measurements were per-
formed before treatment, after the second course or earlier in
case of early progression, and every two cycles thereafter, and
were evaluated according to the WHO criteria for response (17).
In case of progressive disease patients were taken off study.
Drug and Drug Administration. Pharmacia Corpora-
tion supplied Brostallicin in vials, as freeze-dried powder for
injection containing 1 and 10 mg of active drug. The vials were
stored at 5°C protected from light. The content of the vials
was reconstituted with 2 ml and 10 ml of dextrose 5%, respec-
tively, using a plastic syringe. The calculated dose to be admin-
istered was put in a Baxter infusion bag containing 100 ml of
dextrose 5%. The solution was kept at 2–8°C protected from
light until administration. Brostallicin was administered within
4 h from drug preparation. With the exception of the first and
second course, in which patients were hospitalized for pharma-
cokinetic sampling, patients were treated on an outpatient basis.
Prophylactic antiemetics were not allowed during the first cycle
of treatment.
Dosage and Dose Escalation. Brostallicin was adminis-
tered as a 10-min i.v. infusion every 3 weeks. On the basis of
animal data the starting dose was 0.85 mg/m2, corresponding
approximately to one-tenth of the LD10 in mice. Dose escalation
proceeded by an accelerated phase consisting of 100% incre-
ments over the previous dose level in cohorts of 1 patient each.
The accelerated scheme was chosen because of the linear phar-
macokinetic behavior of the drug in animals. During the accel-
erated phase intrapatient dose escalation was allowed if the
patient experienced only toxicities grade 0–1, and provided that
1 patient had completed one cycle at the escalated dose level,
and no side effects of grade 3 and 4 were observed at the higher
dose level. This accelerated phase was terminated at the first
occurrence of DLT or the second instance of grade 2 toxicity in
the first course. Additional dose escalations were based on the
prior dose level toxicity allowing a dose escalation of 15–50%
in cohorts of at least 3 patients. DLT was defined as any more
than or equal to grade 3 nonhematological toxicity attributable
to Brostallicin, with the exception of nausea and vomiting
responding to antiemetic treatment, and a transient grade 3
increase in transaminases lasting 7 days. Treatment-related
neurotoxicity of grade 2 or more was also defined as DLT.
Grade 4 neutropenia for at least 7 days or complicated with
infection of grade 2, febrile neutropenia, or thrombocytopenia
with PLTs 10  25  109/liter for 7 days, or PLTs 10 
109/liter of any duration determined the hematological DLT.
The MTD (or recommended Phase II dose) was defined as the
highest dose to be administered at which 0 of 6 or 1 of 6 patients
experienced DLT, with the next higher dose having at least 2 of
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3 or 2 of 6 patients encountering DLT. Once the MTD was
reached, additional patients were treated at the same dose level,
to characterize the safety profile of Brostallicin at the expected
Phase II dose. If a patient encountered DLT, the dose of Bros-
tallicin was to be decreased to the next previous level at retreat-
ment. The treatment was resumed when ANC had recovered to
1.5  109/liter, and the PLT count to 100  109/liter, and
nonhematological toxicity had recovered to less than grade 2. In
case the toxicity had not recovered within 2 weeks of the
planned retreatment time, the patient went off study.
Pharmacokinetic Analysis. Eleven blood samples of 6
ml were taken on the first day of cycles 1 and 2 from the arm
opposite of the infusion site via an i.v. canula before adminis-
tration (predose); at the end of infusion; at 5, 15, and 30 min;
and 1, 2, 4, 8, 10, and 24 h after the end of infusion. The blood
was collected in tubes containing sodium heparin and was
immediately centrifuged at 1200  g at 4°C for 10 min. Plasma
was aliquoted and stored at 	80°C in the dark until analysis.
Plasma samples were assayed using a specific and sensitive
method based on liquid chromatography with tandem-mass
spectrometric detection using a turbo-ionspray interface. The
sample pretreatment procedure involved a solid-phase extrac-
tion of 400-l sample aliquots using 96-well-solid-phase extrac-
tion plates [Isolute C2(EC); 50 mg for each well]. The deuter-
ated version of Brostallicin ([2H4]PNU-166196A) was used as
an internal standard. The lower limit of quantitation of the assay
was 0.1 ng/ml, and the overall chromatographic run time was 5
min. The assay showed an acceptable interday and intra-assay
precision and accuracy (coefficient of variation 10%).
For each patient the pharmacokinetic parameters were cal-
culated by standard noncompartmental methods. Although lim-
ited sampling time points were available up to 24 h, pyruvate
kinase parameters for all of the patients, including half-lives,
were calculated. The Cmax was put on par with the observed
concentration directly at the end of infusion as read directly
from the raw data. For each patient, the AUC was calculated up
to the last detectable concentration (AUC0-tz), with the linear
trapezoidal rule and extrapolated to infinity (AUC0-inf) using the
terminal rate constant (k), estimated by linear-regression analy-
sis of the final concentration-time data. The T1/2 was calculated
as ln2/k, the total plasma CL as dose divided by AUC0-inf, and
the V as CL divided by k. T1/2 was evaluated using at least three
concentration time points of the terminal phase. V at steady state
was calculated as: mean residence time  CL.
Hematological pharmacodynamics in the first cycle were
evaluated using nadir values of ANCs, PLT counts, and WBC
counts, determined on a twice weekly basis in all of the patients.
Relationships between various exposure measures and drug-
induced myelosuppression were performed using both absolute
nadir values during the first treatment course or by using the
percentage decrease in blood cell count at nadir. This latter
variable was calculated as: % decrease 
 [(pretreatment
count 	 nadir count)/pretreatment count]  100.
Statistical Analysis. All of the pharmacokinetic data are
presented as mean values  SD, unless stated otherwise. The
relationship between peak concentration or AUC and adminis-
tered absolute dose was evaluated by a least-squares linear
regression analysis. The effect of drug dose on CL, V, and T1/2
was analyzed using a Kruskal-Wallis multiple comparison test,
followed by Dunn’s test to detect significantly different groups.
The effect of repeated drug administration on drug CL was
tested by a paired (two-tailed) Student’s t test at a hypothesized
mean difference of 0. Interindividual variability in kinetic pa-
rameters was evaluated by the coefficient of variation, expressed
as a percentage of the ratio of the SD and the observed mean
value. For this purpose, CL was calculated using the absolute
dose in mg (CL in liters/h) or the BSA-corrected dose in mg/m2
(CL in liters/h/m2). The level of significance was set at P 

0.05. Statistical correlations between exposure measures and
toxic side effects or patient characteristics were evaluated using
Spearman’s correlation coefficient and least-squares linear re-
gression analysis. All of the statistical evaluations were per-
formed on the NCSS v5.X software package (J. L. Hintze, East
Kaysville, UT) except the correlation analysis performed on
SAS System V6.12.
RESULTS
Twenty-eight patients (16 male and 12 female), with a
median age of 55 years were enrolled into the study between
October 1999 and June 2001. Patient characteristics are listed in
Table 1. All but 3 of the patients received prior chemotherapy.
Because 1 patient did not start treatment for personal reasons, 27
patients were actually treated and evaluable for toxicity. The
total and median number of courses was 73 and 3 (range, 1–12).
Dose levels studied were 0.85 (n 
 1), 1.7 (n 
 1), 3.4 (n 
 3),
5.1 (n
 3), 7.5 (n
 3), 10 (n
 6), 12.5 (n
 8), and 15 mg/m2
(n 
 2). In 1 patient treated at 15 mg/m2 the dose was reduced
in the second cycle after experiencing DLT in the first cycle.
Table 1 Patient characteristics









Median 1 (range 0–2)





Sarcoma (including GIST) 5
Cervix 2b
Non-small cell lung 3





Chemotherapy and radiation 5
None 3
a Adenocarcinoma with unknown primary.
b One patient with a double tumor (cervix/non-small cell lung
cancer).
c PS, performance score.
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DLT. At the first dose levels (0.85 and 1.7 mg/m2) no
toxicity above CTC level 1 was noted. At dose level 3.4 mg/m2
the first 2 patients experienced nausea grade 2 and vomiting
grade 3 shortly after the drug infusion. Therefore, 5HT3 inhib-
itors were added to the regimen to prevent this observed early
onset emesis. At this dose the accelerated phase was terminated,
and 2 more patients were studied at this level. No DLT was
observed until 12.5 mg/m2. The dose was raised to 15 mg/m2. At
this dose both patients experienced DLT consisting of grade 4
neutropenia lasting 7 days, and 1 patient also experienced
grade 4 thrombocytopenia. This patient developed intestinal
bleeding of a colon tumor, and bacteriaemia during ANC grade
4 and PLTs grade 4 (neutropenic sepsis). Five additional pa-
tients were then treated at the next lower dose level of 12.5
mg/m2. Although no DLTs had been observed in the first 3
patients treated at this dose level, of the additional 5 patients, 3
developed DLT consisting of uncomplicated neutropenia grade
4 for 8 days. Thus, in accordance with the protocol the dose
level of 12.5 mg/m2 could not be considered the MTD. How-
ever, the patients treated at 12.5 mg/m2 who experienced pro-
longed uncomplicated neutropenia were retreated for, respec-
tively, 5, 1, and 3 cycles at the same dose under carefully
controlled conditions with biweekly blood sampling because of
the uncomplicated nature of the neutropenia. In these subse-
quent cycles no DLT was observed. Three additional patients
were treated at the next lower dose level of 10 mg/m2. At this
level no DLTs were observed. So according to protocol defini-
tions the RD of Brostallicin for Phase II trials was set at 10
mg/m2 once every 3 weeks. However, because at 12.5 mg/m2
only 3 of 28 courses yielded DLT and retreatment at the same
dose did not lead to recurrence of DLT, in case of carefully
controlled conditions a dose of 12.5 mg/m2 once every 3 weeks
could be considered.
Hematological Toxicity. Hematological toxicities ob-
served are listed in Table 2. Leukopenia, more specific absolute
neutropenia, was dose-dependent. The neutrophil nadir was
recorded in the second week with recovery during the third
week in the majority of patients (recovery: in cycle 1 median 6
days, range, 2–14; all cycles median 7 days, range, 2–18). Grade
4 neutropenia was first observed at 10 mg/m2. At 12.5 mg/m2,
6 of 8 patients developed grade 4 neutropenia in cycle 1, lasting
8 days in 3 of these patients. The degree of leukopenia did not
correspond to the degree of neutropenia, suggesting selective
neutrophil damage. Neutropenia did not seem to be cumulative.
Thrombocytopenia grade 1–2 was observed in 6 of 27 patients
and in 21% of cycles. Six patients in total developed grade 3
thrombocytopenia over all cycles. Thrombocytopenia grade 4
occurred in only 1 patient receiving the highest dose of 15
mg/m2. Thrombocytopenia did not appear to be cumulative,
because 4 of 9 patients of cohort 12.5 mg/m2 developed throm-
bocytopenia grade 3 at their first course and not in latter courses.
However, the median number of courses administered was only
3. Anemia emerging during treatment grade 1–3 was observed
in 21 of 27 patients (56% of cycles). Anemia grade 4 was not
noted.
Table 3 Summary of worst treatment emergent nonhematologic toxicity by cycle (all cycles)a
Dose level
(mg/m2) No. of patients No. of cycles
Nausea/Vomiting Fatigue Diarrhea
1⁄2 3⁄4 1⁄2 3⁄4 1⁄2 3⁄4
0.85 1 2 2 — — — — —
1.7 1 2 — — 1 — 1	 —
3.4b 3 7 2 2 5 1 3 —
5.1 3 15 6 — 13 0 3 —
7.5 3 8 6 — 7 1 1 —
10 6 9 4 1 2 1 — —
12.5 8 28 10 — 10 2 4 —
15c 2 2 4 — 7 — 1 —
a Expressed in number of cycles worsening by 1 CTC grade over baseline.
b After this dose levels, emesis prophylaxis with 5HT3 inhibitors was started.
c One patient received one course with 15 mg/m2 and thereafter 12.5 mg/m2.
Table 2 Hematological toxicity in first cyclea





subsequent cyclesCTC grade: 1–2 3–4 1–2 3–4
0.85 1 — — — — — —
1.7 1 — — — — — —
3.4 3 — — — — — —
5.1 3 3 — 1 — — —
7.5 3 1 1 — — — —
10 6 1 4 1 — — —
12.5 8 1 7 4 4 3 —
15 2 — 2 1 1 2 NA
a Expressed in number of patients scored to the worst CTC grade experienced during the first treatment cycle.
b ANC, neutropenia; PLT, thrombocytopenia; NA, not applicable.
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Nonhematologic Toxicity. Major nonhematologic side
effects observed are listed in Table 3. Toxicity was mild and
consisted of nausea/vomiting, fatigue, and a transient rise of
transaminases (maximum grade 2). Nausea and vomiting grade
1–2 was observed in 17 patients (63%) within 24 h after treat-
ment start (early onset emesis), and only 1 patient (3.5%)
experienced grade 3 vomiting. No delayed emesis was observed.
At the dose levels of 3.4 mg/m2 prophylactic antiemetics were
introduced (5HT3 blocking agents). Thereafter, nausea could be
limited to grade 1–2. Treatment emergent fatigue grade 1–2 was
noted in 45 of 73 cycles (17 of 27 patients), and 5 patients
developed fatigue grade 3–4 without any correlation with ane-
mia. Fatigue was observed in all of the marginally pretreated
patients, including the 3 chemonaive patients. A transient rise of
transaminases, not attributable to the study drug, was noted in 4
patients but not during all of the courses. In 3 patients a
hypersensitivity reaction was noted. The first patient developed
a transient skin rash at dose level 10 mg/m2 only in her first
course. The second patient was treated at 12.5 mg/m2 and
became hypotensive with tachycardia at the fifth cycle. At the
sixth cycle premedication (dexamethasone 10 mg i.v.) could not
prevent the reoccurrence of these symptoms, and the patient
went off study. The third patient also treated at 12.5 mg/m2
developed short-lasting grade 2 fever and thoracic pain, shortly
after the seventh administration, and went off study.
Pharmacokinetics and Dynamics. Pharmacokinetic
studies were performed in all 27 of the evaluable patients during
the first course and 20 patients in the second course of Brostal-
licin. A summary of pharmacokinetic data are given in Table 4.
The plasma concentration-time profiles of Brostallicin were
very similar between the patients. These profiles were charac-
terized by peak concentrations occurring immediately after ces-
sation of the infusion. This was followed by a rapid decline in
the plasma concentrations in an apparent multiexponential fash-
ion, with a short terminal half-life of 4.69 1.88 h. Overall, the
total plasma CL was relatively slow (mean, 9.61  2.81 and
10.22  3.42 liters/h/m2) in the patients that underwent the first
and second cycle, respectively. No statistical difference was
evident between the two cycle of treatment for the CL value
(paired t test) with a small V of only 7.72  2.62 liters/m2,
suggesting limited distribution toward the extravascular com-
partment.
The relationships between peak concentration or AUC
achieved and the absolute dose of Brostallicin administered, is
shown in Fig. 2, and indicate linear behavior. The values for total
plasma CL of Brostallicin observed at the three lowest dose levels
were slightly higher compared with the other dose levels. This
likely relates to underestimation of the total systemic exposure
resulting from constraints in assay sensitivity, precluding accurate
Fig. 2 Relationship between Cmax and dose (top), and AUC and dose
(bottom).
Table 4 Summary of Brostallicin pharmacokinetics as a function of dose (first course)a
Dose (mg/m2) n Cmax (ng/ml) T1/2 (h) AUC (ng/h/ml) CL (liter/h/m2)
V at steady
state (liter/m2)
0.85 1 114 0.85 53 13.0 4.5
1.7 1 196 2.12 103 15.2 9.20
3.4 3 504 (352–625) 3.60 (2.1–6.0) 280.2 (228–346) 11.7 (9.4–14.6) 10.0 (6.6–16.1)
5.1 3 998.7 (936–1090) 5.80 (2.2–9.1) 567.7 (408–830) 9.3 (5.7–11.9) 8.30 (4.3–11.4)
7.5 3 1369.8 (997–1681) 4.84 (4.4–5.5) 808.5 (713–908) 9.0 (7.7–10.0) 7.2 (5.8–8.0)
10 6 1689.9 (920–2006) 5.70 (3.4–8.6) 1096.6 (997–1311) 8.60 (7.1–11.2) 8.5 (5.8–11.9)
12.5 8 2550.8 (1776–318) 4.70 (4.2–6.5) 1424.1 (1167–1617) 8.3 (7.6–10311) 6.90 (5.1–10.4)
15 2 2784 (2569–2999) 4.48 (4.1–4.9) 2011.4 (1779–2244) 7.0 (6.2–7.8) 5.70 (5.2–6.2)
Overall meanb 4.69  1.88 9.33  2.38 7.72  2.62
a Mean values with range in parenthesis.
b Mean values with SD.
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determination of the terminal disposition phase at the lower dose
levels. However, the total plasma CL of Brostallicin was not
significantly different between the various dose levels (P
 0.123,
Kruskal-Wallis test), suggesting a linear and dose-independent
pharmacokinetic behavior. Likewise, the estimated T1/2 (P 

0.264) and the V (P
 0.428) were relatively constant in all of the
subjects and independent of the administered dose. The AUC
extrapolated from the last time point (24 h) up to infinitive time was
1% in all of the subjects (0.57% 0.31). The mean (SD) ratio
of total plasma CL obtained during cycles 1 and 2 was 0.99 0.28
suggesting that repeated administration of Brostallicin had no
influence on total body CL and was not associated with drug
accumulation (data not shown).
Sigmoidal maximum effect modeling of pharmacokinetic and
hematological toxicity data revealed that both the AUC and Cmax of
Brostallicin were significantly correlated with hematological tox-
icity parameters, including the lowest observed value during the
treatment interval (i.e., nadir), and the maximum percentage de-
crease in ANC, PLT count, and WBC count (Fig. 3).
To explain the observed interpatient variability in Brostal-
licin pharmacokinetics, relationships were evaluated between
individual kinetic parameters and several other patient charac-
teristics, including BSA, age, serum albumin, renal function
(creatinine), and hepatic function (AST and ALT; Table 5). No
clinically significant correlation was observed between Cmax or
AUC and BSA, serum albumin, creatinine, or age.
Fig. 3 Scatterplots depicting
the relationship between ANC
decrements during the first time
course and AUC or Cmax of
Brostallicin (A, AUC; B, Cmax).
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Antitumor Activity. No complete responses were seen.
One patient with extensive liver metastases of a gastrointestinal
stromal tumor had a partial response at a dose level of 5.1
mg/m2 lasting 16 months. Two other patients, 1 with a synovial
sarcoma and 1 with a cervix cancer/non-small cell lung cancer,
had disease stabilization of 13 and 16 weeks at the dose level
12.5 mg/m2.
DISCUSSION
The current study was performed to explore the safety,
tolerability, and pharmacokinetics of Brostallicin, a novel DNA
MGB. The compound shows broad antitumor activity in pre-
clinical models and a level of in vitro myelotoxicity on human
hematopoietic progenitor cells dramatically reduced in compar-
ison with that of other MGBs. It is conceivable that Brostallicin
exhibits different biological properties because it may have a
different ability to alkylate DNA in the minor groove with a
different sequence specificity. Characterizing the pharmacolog-
ical properties of Brostallicin, mechanistic studies have sug-
gested that its antitumor activity is increased in cells with a high
GSH/GST content. This finding has potential value in cancer
treatment, because GSH and GST play a role in cellular resist-
ance to different cytotoxic drugs, and the majority of human
tumors display increased levels of GSH and/or GST with respect
to normal tissues.
We determined (according to the protocol definitions) the
MTD of Brostallicin administered by 10-min i.v. infusion given
once every 3 weeks at 10 mg/m2. However, because at 12.5
mg/m2 only 3 of 28 courses yielded DLT (consisting of pro-
longed uncomplicated neutropenia grade 4), and retreatment at
the same dose did not lead to recurrence of DLT, in case of
carefully controlled conditions a dose of 12.5 mg/m2 once every
3 weeks could also be considered. The toxicity profile of this
agent is mainly determined by reversible myelotoxicity, partic-
ularly neutropenia. At 12.5 mg/m2 grade 3 and 4 neutropenia
was recorded in 7 of 26 cycles (27%). At the RD (10 mg/m2)
grade 3 or 4 neutropenia occurred in 4 of 8 cycles (all of them
in the first cycle). The nadir value occurred approximately at
day 11; the median duration of grade 3 and 4 was 6.5 days
(range, 3–8 days). No double WBC nadir occurred, at variance
with the MGB carzelesin (18). Nausea and vomiting were also
recorded, but were well manageable with antiemetics. Special
care was taken for hepatotoxicity, because in preclinical studies
the liver was identified as another target of Brostallicin. In
contrast to ecteinascidin-743, a currently investigated MGB, no
major transaminitis was noted (19). In any other aspect Bros-
tallicin was well tolerated.
After the administration of Brostallicin to various animal
species, plasma CL was slow (11.7, 8.0, and 12.6 ml/min/kg in
mice, dogs and monkeys, respectively), and represented 25%
of the hepatic blood flow (20). The V of the central compart-
ment exceeded the plasma volume by 5–6-fold, and the V at
steady state was 310–439 ml/kg, suggesting a moderate distri-
bution into tissues. This is in agreement with the high hydro-
philic nature of this compound. In our study the CL of Brostal-
licin in cancer patients was similarly slow, with a mean value of
10 liters/h/m2 albeit with a relatively fast T1/2 of 5 h. As
predicted from the animal pharmacokinetic data, the V at steady
state was small, 10 liters/m2. Thus, the pharmacokinetic re-
sults in our study in humans are in line with the results of studies
in different animal species, which had clear predictive value for
pharmacokinetic studies of Brostallicin and are very similar to
those of tallimustine (4, 21, 22).
In the present study, Brostallicin demonstrated linear and
dose-independent pharmacokinetics over the total dose range
studied, without any major time dependency. Repeated admin-
istrations of Brostallicin to the same cancer patient had no
measurable effect on either Cmax and AUC or CL, which indi-
cates a lack of accumulation and/or autoinduction.
A moderate degree of interpatient variability in kinetic
parameters was apparent, with 2-fold variation in AUC val-
ues. To explain the observed interpatient variability in Brostal-
licin pharmacokinetics, relationships were evaluated between
individual kinetic parameters and several other patient charac-
teristics. No clinically significant correlation was observed be-
tween Cmax or AUC and BSA, serum albumin, creatinine, or
age, suggesting that reduced starting doses are not required in
elderly patients. Although significant Ps were obtained with the
baseline and peak transaminase evaluations when correlated to
pyruvate kinase parameters of Cmax and AUC, low Spearman
coefficients less than the absolute value of 0.7 indicate there is
a minimal association between these parameters, and as such it
can be concluded that these relationships are not of clinical
significance. Additional analysis is clearly required, e.g., using
Table 5 Correlation between Brostallicin pharmacokinetics and patient characteristicsa
Variable n
Cmax AUC
rb p r p
Age 27 	0.01 NS 	0.03 NS
BSA 27 	0.08 NS 0.03 NS
Baseline albumin 27 	0.21 NS 	0.21 NS
Baseline creatinine 27 	0.58 0.002 	0.50 0.008
Baseline AST 27 0.39 0.047 0.44 0.022
Baseline ALT 27 0.41 0.036 0.37 NS
Peak creatinine 27 	0.66 0.0002 	0.59 0.001
Peak AST 27 0.43 0.025 0.45 0.019
Peak ALT 27 0.59 0.001 0.59 0.001
a Only data from the first treatment course were taken into account.
b r, Spearman’s correlation coefficient; p, probability value; NS, not statistically significant.
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a multiple regression approach to construct a clinically relevant
model that will include patients with altered liver and/or renal
function.
Relative to the absolute CL of Brostallicin (expressed in
liters/h), the interpatient variability in CL remained in a similar
order of magnitude after correction for the BSA of individual
patients (expressed in liters/h/m2), with coefficients of variation
of 30.8% and 28.5%, respectively, indicating that BSA contrib-
utes to only 7.5% of the total kinetic variability between pa-
tients. In addition, a linear-regression analysis of absolute CL of
Brostallicin versus BSA did not result in a significant relation-
ship (r 
 0.23; P 
 0.30). This suggests that BSA is not a
significant predictor of Brostallicin CL and that flat-fixed dos-
ing regimens might be applied in future studies without com-
promising overall safety profiles.
The pharmacodynamic analysis was focused on hemato-
logical toxicity, particularly the dose-limiting neutropenia. The
modeling of the pharmacokinetic and pharmacodynamic data in
the present study revealed a significant relation between the
hematological toxicity, and both AUC and Cmax of Brostallicin.
One patient with extensive liver metastases of a gastroin-
testinal stromal tumor, a known chemotherapy-resistant tumor
type, clearly responded to the treatment with an objective partial
response lasting 16 months. Two patients, 1 with synovial
sarcoma and 1 with cervix cancer/non-small-cell lung cancer
demonstrated disease stabilization for, respectively, 16 and 13
weeks. Phase 2 studies on Brostallicin are currently ongoing
using the 3-weekly schedule.
In conclusion, the RD for Brostallicin is 10 mg/m2 given
once every 3 weeks. At this dose the plasma systemic exposure
(AUC) is twice as high as the exposure needed in mice models
to achieve antitumor effects. Alternatively, a flat/fixed dosing
can be considered. The current clinical findings and the novel
mechanism of action of Brostallicin suggest that additional
clinical research on this agent is clearly warranted.
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